SEC Filing Summary: Integrity Applications, Inc. (10-Q)
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended September 30, 2011. The registrant is Integrity Applications, Inc. (a Delaware corporation), which operates through its wholly-owned Israeli subsidiary, A.D. Integrity Applications Ltd. The company is a development-stage medical device firm focused on the design and commercialization of the GlucoTrack DF-F, a non-invasive glucose monitoring device for diabetics. The company has not yet generated any revenue and is dependent on external financing.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2011 | Nine Months Ended Sep 30, 2011 | Cumulative (Inception to Sep 30, 2011) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(708,708) | $(1,765,629) | $(11,918,809) |
| Loss Per Share (Basic/Diluted) | $(0.14) | $(0.35) | N/A |
| Cash and Cash Equivalents | $2,476,169 (as of Sep 30, 2011) | ||
| Total Assets | |||
| Total Liabilities | $1,213,051 (as of Sep 30, 2011) | ||
| Stockholders' Equity | $1,559,686 (as of Sep 30, 2011) | ||
| Operating Cash Flow (9 months) | $(1,337,410) |
Material Changes vs. Prior Period
- Expenses: Research and Development (R&D) expenses increased significantly to $461,077 for the quarter (from $189,104 in the prior year quarter) and $1,242,191 for the nine-month period (from $678,200). This increase is attributed to higher stock-based compensation, employee salaries, and costs to expedite product readiness for clinical trials.
- General & Administrative (G&A): G&A expenses rose to $239,169 for the quarter (from $105,502) and $493,905 for the nine-month period (from $331,854), driven by professional fees related to capital raising and the corporate reorganization.
- Financing Expenses: Net financing expenses decreased to $8,462 for the quarter (from $388,133) and $29,533 for the nine-month period (from $1,145,136), primarily due to the absence of stock-based interest compensation on convertible notes which were present in the prior year.
- Liquidity: Cash balances increased from $1,494,248 at year-end 2010 to $2,476,169 at September 30, 2011, fueled by a private placement offering.
Outlook, Risks, and Management Commentary
- Going Concern: The company has incurred cumulative losses of nearly $12 million and negative operating cash flows of $8.7 million since inception. Management and auditors have expressed substantial doubt about the company's ability to continue as a going concern without additional financing.
- Capital Raising: During the nine months ended September 30, 2011, the company raised approximately $2.4 million through the issuance of common stock in a private placement at $6.25 per share. Management believes current cash reserves will support operations for at least 12 months.
- Product Development: The GlucoTrack DF-F has not received regulatory approval in the US, EU, or elsewhere. The company plans to begin formal clinical trials in Israel and Europe in Q2 2012 and in the US in late 2012, pending FDA protocol approval.
- Risks: Key risks include the failure to obtain necessary financing, delays in clinical trials, lack of market acceptance, and the inability to secure regulatory approvals.
Investor Verification Checklist
- Runway Validation: Verify if the $2.4 million cash balance is sufficient to fund the planned clinical trials in 2012 without immediate dilution.
- Regulatory Status: Confirm the timeline and requirements for FDA approval of the GlucoTrack DF-F device.
- Dilution Risk: Review the terms of the private placement, including the 10% placement agent warrants and anti-dilution protections for investors until September 2012.
- Debt Obligations: Examine the terms of the long-term loans from stockholders (approx. $626k), which are repayable only upon profitability but include linkage adjustments based on the Israeli Consumer Price Index.
- Going Concern: Assess the likelihood of securing additional capital given the lack of revenue and the "substantial doubt" qualification in the financial statements.